SODIUM IODIDE I 131

Post-LOE

sodium iodide i-131

PharmaIN

ANDAORALSOLUTION

Approved

Feb 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

SODIUM IODIDE I 131 (sodium iodide i-131) by PharmaIN is sodium-iodide symporter (nis) protein, in thyroid follicular cells. Approved for hyperthyroidism, selected cases of thyroid carcinoma, selected cases of carcinoma of the thyroid. First approved in 2020.

Drug data last refreshed 22h ago

Mechanism of Action

sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I ) which in turn iodinates tyrosine residues of thyroglobulin (tri…

Indications (3)

hyperthyroidism selected cases of thyroid carcinoma

Worked on SODIUM IODIDE I 131 at PharmaIN? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.